je.st
news
Alnylam trial confirms continued effectiveness of RNAi drugs
2015-04-21 13:50:02| Biotech - Topix.net
Trial results released today suggest the lead drug by Alnylam Pharmaceuticals for a rare neurodegenerative disease continues to stop nerve damage after a year, confirming earlier results. The trial is the longest one yet to measure the neuropathic effects of the drug by Alnylam , called Patisiran.
Tags: trial
continued
drugs
effectiveness
Category:Biotechnology and Pharmaceuticals